A non-intoxicating cannabis compound with one well-proven use: cutting seizures in rare severe childhood epilepsy. For everyday anxiety the signal is moderately encouraging but built on small studies; for pain and sleep it is weaker and mixed. Low doses are well tolerated; main concerns are liver enzyme changes at high doses and raising blood levels of other medicines. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT (alanine aminotransferase) | < 25 U/L (men), < 22 U/L (women) | Detects CBD-related liver stress |
| AST (aspartate aminotransferase) | < 25 U/L | Confirms liver injury alongside ALT |
| Bilirubin (total) | < 1.0 mg/dL | Flags more significant liver injury when raised with enzymes |
| INR (if on warfarin) | Per anticoagulation target (typically 2.0–3.0) | Detects CBD-driven increase in bleeding risk |
| Blood pressure | < 120/80 mmHg | Tracks CBD's modest blood-pressure-lowering effect |
Cadence: Baseline, then around 4–8 weeks after starting or a dose increase, and thereafter every 6–12 months for sustained use (more frequently with high doses or interacting drugs).